课题基金 / 基金详情

NISA: Novel approaches for in situ analysis of biomolecules

NISA: Novel approaches for in situ analysis of biomolecules
NISA:生物分子原位分析的新方法
批准号:
EP/L023490/1
负责人:
Helen Cooper
金额:
$189.16万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2014
资助国家:
英国
项目状态:
已结题
起止时间:
2014 至 --

项目摘要

项目成果

Helen Cooper的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of the research is to develop novel approaches for the analysis of biomolecules, and in particular proteins, directly from their natural (or actual) environment, i.e., to develop approaches for in situ biomolecular analysis. Proteins are the work-horses of the cell and perform all the functions required for life. They also find uses as therapeutics and in consumer products. To gain insight into the various and specific roles of proteins in life processes, or to determine the therapeutic efficacy of protein drugs, or to establish the environmental fate of protein additives in consumer products, it is necessary to be able to analyse proteins at a molecular level. Mass spectrometry, in which ionised molecules are characterised according to their mass-to-charge, is ideally suited to this challenge, offering high sensitivity, broad specificity (all molecules have a mass), and the capability for chemical structure elucidation. The ultimate goal is to link molecular analysis directly to molecular environment. Much like a forensics officer tasked with determining the presence of an illicit substance, there is much greater reliability and credibility afforded to an analysis performed at the scene of the crime than to one performed following removal of the sample to a separate location and alternative surroundings.Growing evidence suggests in situ protein analysis has groundbreaking roles to play in biomarker discovery, diagnosis & early detection of disease, targeting therapeutics (personalised medicine) and assessment of therapeutic efficacy. The benefits of in situ protein analysis can be illustrated by considering a thin tissue section through a drug-treated tumour. In principle, in situ analysis would inform on drug-target interactions (i.e., is the drug binding to the correct protein?). Moreover, with in situ protein analysis the capacity for artefact introduction as a result of sample preparation (e.g., application of a matrix) or sample damage is eliminated.Nevertheless, a number of challenges exist. Proteins are large molecules associated with a vast array of chemical modifications, and which form loosely-bound complexes with themselves, other proteins and other molecule types. It is not only their chemical structure but also their overall 3-D structure which dictate their function. Other molecular classes that are hugely important in biological processes also have an intricate relationship with proteins. Any in situ mass spectrometry approach needs to be able to meet these analyte-driven challenges, i.e., it must be capable of (a) measuring proteins and characterising any modifications, (b) detecting protein complexes and determining their constituents, (c) providing information on 3-D structure, and (d) detecting other relevant molecular classes. Moreover, there are technique-driven challenges for in situ analysis including inherently high sample complexity and wide ranging concentrations, and opportunities for quantitation.The research will meet these challenges by developing a newly emerging in situ approach, liquid extraction surface analysis mass spectrometry, in combination with two complementary types of ion mobility spectrometry (which can either provide information on 3-D structure, or separate ionised molecules in the mass spectrometer on the basis of their 3-D shape) and a structural elucidation strategy known as electron-mediated dissociation mass spectrometry.The research will be undertaken primarily at the University of Birmingham in the Advanced Mass Spectrometry Facility in the School of Biosciences and the School of Chemistry mass spectrometry facility. The programme involves a number of academic and industrial collaborators and additional research will be carried out during scientific visits to National Physical Laboratory (NPL), Thermo Fisher Scientific, Waters, Owlstone, Florida State University, Texas A&M University and Université d'Aix-Marseille.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s13361-016-1482-1
发表时间: 2016-12
期刊: JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
影响因子: 3.2
作者: [Creese, Andrew J., Cooper, Helen J.]
通讯作者: Cooper, Helen J.
DOI: 10.1016/j.ijms.2017.10.009
发表时间: 2019-03-01
期刊: INTERNATIONAL JOURNAL OF MASS SPECTROMETRY
影响因子: 1.8
作者: [Griffiths, Rian L., Sisley, Emma K., Cooper, Helen J.]
通讯作者: Cooper, Helen J.
DOI: 10.1007/s13361-015-1326-4
发表时间: 2016-04
期刊: Journal of the American Society for Mass Spectrometry
影响因子: 3.2
作者: [Cooper HJ]
通讯作者: Cooper HJ
DOI: 10.1104/pp.16.01450
发表时间: 2017-03-01
期刊: PLANT PHYSIOLOGY
影响因子: 7.4
作者: [Eaves, Deborah J., Haque, Tamanna, Franklin-Tong, Vernonica E.]
通讯作者: Franklin-Tong, Vernonica E.
Native ambient mass spectrometry for membrane proteins
  • 批准号:
    EP/Y004604/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $68.89万
  • 财政年份:
    2023
  • 负责人:
    Helen Cooper
  • 依托单位:
NAMS: Native ambient mass spectrometry
  • 批准号:
    EP/S002979/1
  • 项目类别:
    Fellowship
  • 资助金额:
    $158.19万
  • 财政年份:
    2019
  • 负责人:
    Helen Cooper
  • 依托单位:
A new mass spectrometer for structural proteomics and protein imaging
  • 批准号:
    BB/S019456/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $79.17万
  • 财政年份:
    2019
  • 负责人:
    Helen Cooper
  • 依托单位:
A new tool to support drug discovery: Native LESA mass spectrometry (NESA)
  • 批准号:
    EP/R018367/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $52.37万
  • 财政年份:
    2018
  • 负责人:
    Helen Cooper
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: